Benjamin Prohaska
Physician Assistant · Reno, NVNPI 1174652143
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Mannkind Corporation at 31.8% of the total. Reporting peaked in 2023 at $12,145 and has fallen 63.2% since, to $4,464 in 2025. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 813 payments — averaging $37.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$10K
- Sanofi-aventis U.S. LLC$5K
- Novo Nordisk$4K
- Corcept Therapeutics$3K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- plus $6K from 32 others
What the payments were for
- Consulting fees$8,45528%
- Speaking & faculty fees$5,16017%
- Travel & lodging$2,5958%
- Food & beverage$14,30347%
- Education$1881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 133 | $9,766 |
| Sanofi-aventis U.S. LLC | 41 | $5,274 |
| Novo Nordisk | 58 | $4,272 |
| Corcept Therapeutics | 87 | $2,524 |
| Lilly USA, LLC | 92 | $1,381 |
| Boehringer Ingelheim | 55 | $1,043 |
| Xeris Pharmaceuticals, Inc. | 62 | $850 |
| Medtronic | 51 | $808 |
| AstraZeneca(2 entities) | 26 | $702 |
| Amgen(2 entities) | 32 | $679 |
| Abbott | 39 | $517 |
| Radius Health, Inc. | 19 | $389 |
| Bayer | 21 | $384 |
| Insulet Corporation | 11 | $313 |
| Recordati_rare_diseases_inc. | 17 | $301 |
| Dexcom, Inc. | 7 | $285 |
| AbbVie | 10 | $188 |
| Antares Pharma, Inc. | 7 | $139 |
| Verity Pharmaceuticals Inc. | 4 | $95 |
| Novartis | 5 | $90 |
| IBSA Pharma Inc. | 5 | $87 |
| Tandem Diabetes Care, Inc. | 3 | $86 |
| Amarin Pharma, Inc. | 5 | $80 |
| BETA Bionics, Inc. | 3 | $77 |
| Ascensia Diabetes Care US Inc. | 4 | $57 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Alfasigma USA, Inc. | 2 | $35 |
| Zealand Pharma US, Inc. | 2 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $23 |
| RGH Enterprises LLC | 1 | $22 |
| Nevro Corp. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$7,674
- TZIELD$4,577
- RYBELSUS$3,430
- Korlym$1,002
- DEXCOM G6 TRANSMITTER$150
How this compares
$30,701 in reported general payments places this provider in the 95th percentile of 881 physician assistant providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 62 | $1,933,776 |
| MounjaroTirzepatide | 960 | $1,388,478 |
| OzempicSemaglutide | 742 | $1,232,337 |
| RecorlevLevoketoconazole | 34 | $750,480 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 481 | $632,449 |
| JardianceEmpagliflozin | 414 | $550,889 |
| Tresiba Flextouch U-200Insulin Degludec | 270 | $263,390 |
| TrulicityDulaglutide | 145 | $253,958 |
| IsturisaOsilodrostat Phosphate | 11 | $175,004 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $96,464 |
| Tresiba Flextouch U-100Insulin Degludec | 114 | $79,387 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $56,423 |
| FarxigaDapagliflozin Propanediol | 36 | $53,208 |
| TymlosAbaloparatide | 12 | $48,468 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 44 | $38,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $2,524 | $1,933,77662 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,381 | $1,649,3081,125 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $4,272 | $1,274,167787 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $1,043 | $1,212,781914 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $850 | $750,48034 claims |
| Recordati_rare_diseases_inc.Isturisa | $301 | $175,00411 claims |
| AstraZenecaFarxiga | $702 | $53,20836 claims |
| Radius Health, Inc.Tymlos | $389 | $48,46812 claims |
| Antares Pharma, Inc.Xyosted | $139 | $15,89515 claims |
| AbbVieSynthroid | $188 | $1,17917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 881 physician assistant providers in Nevada.
Other physician assistant in Reno
- John LarsenReno$49K
- Laura BiehleReno$36K
- Rebecca SparksReno$16K
- Daniel CollReno$12K
- Cameron WheelerReno$11K
- Julia WronaReno$10K
- Amber FrancoReno$9K
- Paul JohnsReno$8K
- Shannon WeaverReno$7K
- Leila NazparvarReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.